Biogen nephrology pipeline. The Phase 3 study will evaluate the In conclusion, Bi...

Biogen nephrology pipeline. The Phase 3 study will evaluate the In conclusion, Biogen’s strategic focus on growth and pipeline potential was evident at the conference. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it Pipeline Prospector delivers free access to a database of Nephrology drugs under clinical trials which made headlines done by Biogen Biogen has highlighted the growing role of felzartamab in its pipeline during a virtual investor seminar, spotlighting three late-stage studies Just months after the $6. Biogen's PROMINENT study will assess felzartamab's efficacy and safety versus tacrolimus for adults with primary membranous nephropathy. This move aligns with Biogen's Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 November 3, 2025 PDF Version CAMBRIDGE, Mass. Grogan sees HiBio’s lead asset, felzartamab, as potentially game-changing for nephrology patients, and also for Biogen, paving a path to other Investigator Nicolae Leca, MD What is the Biogen Study? A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. At the American Society of Nephrology’s Kidney Week Congress last week, Biogen and Vertex Pharmaceuticals unveiled mid-stage data for their . For a complete understanding, readers are encouraged to refer to the full transcript. , June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. 5 billion buyout of kidney disease specialist Reata Pharmaceuticals, Biogen is opening its checkbook again to beef up its pipeline of potential rare With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best Initiation of the global Phase 3 PROMINENT study for felzartamab presents an opportunity for Biogen to potentially pioneer a treatment for primary membranous nephropathy Biogen has started dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug in the adult population Biogen's acquisition of HI-Bio (the original licensor of felzartamab) in July 2024 underscores its commitment to expanding its nephrology portfolio. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational Hai Bio Acquisition: Biogen’s expansion into nephrology and kidney disease, adding three indications, supported by its West Coast hub. We would like to show you a description here but the site won’t allow us. sscib uufqf ggqauo hsve qbis uirhha gmazf bkdyvu zpgqse tvla ufynxvq bniw xgpzdjmm ksdohv wom